Rheumatology patient no-show rates: benchmarks and chair cost (2026)
Rheumatology patient no-show rates run about 8.6% for new patient referrals, based on the one published regional health system benchmark, and the patients who no-show are the ones who waited longest to schedule after the referral. The cost is concentrated in the infusion suite, where a missed appointment leaves a one-to-four-hour chair, a staffed nurse, and sometimes a mixed drug idle, and pushes a biologic dose past its interval. The fix is not a louder reminder. It is fast first contact, short lead times, two-way rescheduling, and automatic backfill from a wait list. Rheumatology has a wait list long enough that every no-show is also a patient who could have been seen weeks earlier and was not.
This guide covers the published no-show benchmarks and what drives them, what a no-show actually costs a rheumatology practice, why infusion no-shows are the expensive kind, and a six-step plan to reduce and backfill them.
Key Takeaways
- Across 2,167 new rheumatology referrals in one regional health system, 8.6% no-showed, and those patients had waited 33.4 days to call and schedule against 9 days for patients who arrived.
- A large VA medical center measured an 18.8% no-show rate across ten clinics and a marginal cost of $196 per missed visit, and its reminder system moved the rate only from 16.3% to 15.2%.
- MGMA found 37% of medical groups reporting higher no-shows in 2023 and 27% in 2025, with two-way texting and shorter lead times credited by the groups holding steady.
- An infusion no-show costs a chair, a nurse, potentially a drug, and a delayed dose, which is why rheumatology should report infusion no-shows separately from office no-shows.
- Backfill rate belongs next to no-show rate on every report; the practice that refills the chair has not lost the chair.
The Data Behind the Decision
The published rheumatology benchmark comes from Allegheny Health Network. Across 2,167 unique patients referred for ambulatory rheumatology care in 2019, 186 no-showed, an 8.6% rate. Patients who no-showed were younger, and the strongest process predictor was delay: they had waited 33.4 days between the referral and calling to schedule, against 9 days for patients who arrived. November ran highest at roughly 12% (ACR Convergence abstract, 2021). The no-show was decided in the first month after the referral, long before the reminder went out.
The cost side is documented outside rheumatology and transfers directly. At a large Veterans Health Administration medical center, the mean no-show rate across ten clinics was 18.8%, the marginal cost per no-show was $196 in 2008 dollars, and the annual cost across those clinics was $14.58 million. A reminder system implemented there moved the rate from 16.3% to 15.2% over six months (BMC Health Services Research, 2016). The same paper cites a community hospital estimate that no-shows and cancellations produced an annual revenue shortfall of 3% to 14%. A rheumatology infusion chair is a higher-cost slot than any of the clinics in that study.
The trend is flat, not improving. In MGMA's August 2023 poll, 52% of medical groups said no-shows had held steady, 37% said they had risen, and 11% said they had fallen, with some practices adopting fees of $25 for an office visit and others reluctant because of the manual work involved (MGMA, 2023). By August 2025, 60% reported no change, 13% a decrease, and 27% an increase, and the groups that were winning credited frequent digital reminders, two-way texting with tap-to-reschedule, easy cancellation, same-day availability, and shorter lead times (MGMA, 2025). And 82% of patients try to book care outside a practice's regular office hours, which is when the patient who wants to reschedule instead of no-showing actually tries to.
What does a no-show actually cost a rheumatology practice?
Count three things. The slot: an unfilled 20-minute follow-up or 40-minute new patient visit that a wait-listed patient could have used. The chair: an infusion no-show idles a chair for the drug's full duration, a nurse who was staffed for it, and any drug that was already prepared or shipped. The patient: a biologic dose delivered past its interval raises the odds of a flare, and a flare is an urgent visit that displaces someone else. Add the referral relationship. A PCP who hears that their patient never got seen sends the next one elsewhere.
The general math is in average no-show rate and cost. The rheumatology adjustment is that the average hides the distribution: a 6% blended no-show rate can be 3% in follow-ups and 12% in new referrals, and the new referral is the visit with the longest wait behind it and the most revenue ahead of it.
Why are infusion no-shows different?
Because the chair is the asset. An infusion suite runs on chair hours, and every drug has a duration: an hour or two for infliximab in maintenance, longer for rituximab, shorter for some newer agents. A no-show does not free the chair for another infusion the way an empty exam room frees a slot, because the next patient's drug has an interval, an authorization, and a delivery behind it. Backfilling an infusion chair on the day requires a wait list of patients who are inside their interval, authorized, and reachable in the next hour, which is exactly the list most practices do not keep.
Infusion patients also no-show for different reasons. Transportation, a copay they did not expect, an authorization they were told had lapsed, a fear of side effects they did not mention at the last visit. None of those are solved by a reminder. All of them are solved by a conversation the patient can start at 8 p.m., which is why two-way texting keeps showing up in the MGMA data as the tactic that works.
How to reduce no-shows in a rheumatology practice: 6 steps
- Report by visit type. New referral, follow-up, lab-only, infusion. Add lead time and referring practice. The blended number hides the problem.
- Reach referred patients within 24 hours. The 33-day-versus-9-day gap is the largest lever in the published data. First contact by phone, text, and email, from the practice's number, with booking in the same conversation.
- Shorten lead time where you can. Hold a few slots per week for urgent inflammatory referrals and release them from the wait list. A shorter wait is a lower no-show rate.
- Make rescheduling easier than disappearing. Two-way text with tap-to-reschedule, answered at night. A patient who reschedules is not a no-show.
- Keep a live infusion backfill list. Patients inside their interval, authorized, and willing to come on short notice, reachable automatically when a chair opens.
- Track backfill next to no-show. Slots refilled from the wait list are the number that proves the chair was not lost.
What Should Still Go to a Human?
Whether a patient who missed an infusion should be re-dosed on the original schedule or re-loaded is a clinical decision. Fee waivers, balance disputes, and any conversation about why a patient stopped coming that turns into a complaint belong to a person. A patient who no-showed because they felt too sick to come needs a nurse, not a rebooking link. Software should recognize that reply and route it.
Where Clinekt Fits
Clinekt is the patient activation platform for specialty practices: four AI agents that share one memory of every patient and cover the whole journey, from first click to the care between visits. Against no-shows, the Inbound Agent answers the referred patient instantly, screens symptoms, self-schedules qualified patients, and covers after hours, which closes the 33-day gap the ACR data describes. The Recall Agent continuously scans the practice's records for ordered-but-never-scheduled visits, missed infusion intervals, and the patient who no-showed and was never rebooked, reaches them in one two-way thread in the practice's voice, and books them into open slots, reporting found, reached, booked, seen. The Care Management Agent runs monthly check-ins between visits and flags the patient who is about to stop coming before the chair sits empty. Clinekt OS is the one memory behind all of it, so the patient who rescheduled by text in March is recognized when they call in October, and every step is attributed.
Our published result is orthopedic: Baldwin Bone and Joint generated 263 qualified surgical leads and 159 booked appointments, a 60% booking rate, in a single quarter. The no-show mechanism is the same: a patient reached fast, with an open slot and a way to reply, keeps the appointment. More than one million patient interactions have been completed across the platform. Deployment is live the same day, with no IT project, no new staff workflow, and a sync to the EHR. Clinekt is HIPAA compliant and SOC 2 Type II. See the full platform, put your own no-show and chair numbers into the leakage calculator, and book a demo.
Frequently Asked Questions
What is a good no-show rate for a rheumatology practice?
Under 8% for new patient referrals and under 5% for established follow-ups is a reasonable target, with infusion no-shows tracked separately and held as close to zero as the practice can manage. The one published rheumatology benchmark, 8.6% for new referrals across a regional health system, is where many practices start.
Why do infusion no-shows cost more than office no-shows?
A chair is booked for one to four hours, the drug may already be mixed or ordered, and the nurse is staffed. An office no-show costs a 20-minute slot. An infusion no-show costs the chair, the nursing time, potentially the drug, and the delay in the patient's own treatment, which raises the odds of a flare and an urgent visit later.
Do appointment reminders reduce rheumatology no-shows?
Somewhat. One large health system's reminder rollout moved the rate from 16.3% to 15.2% over six months, which is real but small. The larger levers are reaching the patient quickly after the referral, shortening lead time, and two-way texting that lets the patient reschedule instead of disappearing. Read do appointment reminders reduce no-shows for the evidence.
Should a rheumatology practice charge no-show fees?
Some do, typically small amounts for office visits, and MGMA found practices reluctant because of the manual work involved. Fees also do nothing for the infusion chair, where the cost is the drug and the chair time. Backfill from a wait list recovers more than a fee ever will.
How should a rheumatology practice report no-shows?
By visit type (new referral, follow-up, lab-only, infusion), by lead time, and by referring practice, monthly. Report backfilled slots alongside no-shows. A 9% no-show rate with 70% of slots backfilled is a different business than a 9% rate with none.
Enter your infusion chair count and no-show rate in the leakage calculator to see what the empty chairs cost per year, then book a demo and we will show you the backfill report.